Search

Introduction and objective: Obesity has become an important public health issue in Poland. Furthermore, it is one of the most common preventable causes of diseases and mortality. Pharmacological methods of treating obesity have been developing significantly in recent years. Tirzepatide is a new dual incretin receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The aim of this review is to assess the effectiveness of this medication in reducing body weight. Current state of knowledge: According to data from the Central Statistical Office (GUS) in Poland, 65% of men and 49% of women are struggling with the issue of excessive body weight [1]. Obesity in Polish society is steadily increasing in every age group. However, it affects most significantly children aged 7-13 years and adolescents. In 2022, the novel dual GLP and GIP-1 agonist has been registered for the treatment of type 2 diabetes which is not satisfactorily controlled. It can be also used together with diet and physical activity in patients diagnosed with obesity (BMI of 30 kg/m2 or more) or who are overweight (BMI 27-30 kg/m2) and have weight-related health problems such as hypertension, metabolic syndrome, dislipidaemia and diabetes mellitus [2]. Summary: The increasing prevalence of obesity leads to a dynamic search for the most effective pharmacological methods of treating obesity. The combined activation of GLP-1 and GIP receptors by Tirzepatide has been shown to have additional benefits beyond satisfying glucose control. The biological mechanism of action of this medication additionally causes decreased food intake, slowed gastric emptying and enhanced insulin secretion, all of which can contribute to weight reduction. Overall, Tirzepatide represents a promising option for individuals struggling with obesity, offering the potential for significant weight loss in conjunction with lifestyle modifications such as diet and physical activity. [ABSTRACT FROM AUTHOR]

Introduction: Anticoagulants have been discovered and developed over past 100 years. At the beginning unfractionated heparin found its applications, just later to fade into the background of newer and more effective drugs. Patients have been treated with more and more progressive medications -- Low-Molecule-Weight Heparin (LMWH), Vitamin K Antagonists (VKA) and Novel Oral Anticoagulants (NOAC). All of them have many indications but most importantly they are used in prophylaxis and treatment of venous thromboembolism (VTE). Scientists and physicians have been working for years to come up with the perfect drug that has fewer contraindications, side effects and doesn't need continuous anticoagulant monitoring. As for today, deemed a turning point in anticoagulant therapy are inhibitors of factor XI. It is a ground-breaking innovation as it ensures high prevention of thrombotic episodes and guarantees intact physiological hemostasis. Current State of Knowledge: The coagulation cascade and molecules part taking in that have been discovered and described extensively and in detail. Historically, the demand for anticoagulants was always a burning subject. A huge progress has been made in the last one hundred years. Treatment which clinicians are using currently is a combination of drugs used in the past and the novel forms. Unfractionated heparin is the oldest out of all and despite its simple action mechanism and adverse effects, is still a requested drug. Its lighter form, low-molecule-weight-heparin (LMWH) is an enhancement to the previous treatment due to its higher bioavailability and fewer side effects. Vitamin K antagonists (VKAs) are widely spread in medical environment thanks to their expanded mechanism of action, oral administration and reversibility of their overdose, as well as their well-developed anti-side effect therapy. Novel Oral Anticoagulants (NOACs) have been introduced to the market about 10 years ago. In spite of NOACs short period of clinical use, they were a huge change to the previous treating methods. No need of constant checking the coagulation times was a great convenience to both patients and doctors. Currently, the newest innovation in anticoagulant therapy are inhibitors of factor XI. Even though it still undergoes clinical trials, the outcome is promising for the future. Summary: The present article discusses history of anticoagulant drugs, their mechanism of action and usage but also focuses on the recent perspectives and developments as new anticoagulant drugs are being put to the test in therapeutic trials. The review underlines the importance and a big demand for improvements in old therapeutic methods and exploring the new, more suitable ones. [ABSTRACT FROM AUTHOR]

Introduction: The increasing participation of young individuals in sports necessitates a comprehensive understanding of the intricate relationship between nutrition and athletic performance during the critical adolescent years. This introduction sets the stage for an exploration of the dynamic nutritional needs of young athletes, emphasizing the pivotal role of nutrition in supporting growth, energy metabolism, and overall athletic achievement. Current State of Knowledge: The current state of knowledge encompasses an in-depth analysis of key nutritional considerations for young athletes. Examining energy and macronutrient requirements, micronutrient considerations, hydration strategies, and optimal timing of nutrition, this section synthesizes existing research to provide evidence-based guidelines. Furthermore, it addresses the unique challenges posed by different sports and the importance of tailored nutritional approaches for diverse athletic endeavors. The evolving landscape of sports nutrition is also explored, with a specific focus on the benefits and potential risks associated with protein and creatine supplementation. Summary: In summary, this article serves as a comprehensive resource for athletes, coaches, and parents seeking to navigate the intricate intersection of nutrition and young athletes. By elucidating evidence-based strategies and addressing the potential drawbacks and risks associated with certain supplements, the article aims to empower stakeholders with the knowledge needed to make informed decisions regarding the nutritional well-being of young athletes. It underscores the importance of individualized approaches, recognizing the diversity of young athletes and advocating for adaptable nutritional strategies that contribute to both immediate performance gains and sustained health and athletic success. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Education, Health & Sport is the property of Nicolaus Copernicus University in Torun and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Anterior chest wall depression known as Pectus excavatum (PE), is currently the most common congenital chest wall deformation, with incidence estimated at 1/400 births, five times more frequently in boys than girls (5:1 ratio in occurrence). 1 Etiology of this deformity is formed by several hypothesis, including overgrowth of the ribs, developmental failure of the bony thorax or weakness and abnormal flexibility of the sternum. While theoretical concepts of its origin may differ, the common ground is the characteristics of said deformation: a posterior depression of the sternum and the lower costal cartilages. 2 Surgical treatment options were described since 1949 with Ravitch procedure and since then a number of new ones has been developed. For many years Ravitch and Nuss procedures were the main way to treat pectus excavatum, with a growing bias towards latter one. Since the Nuss procedure characterizes with less invasive approach and fever overall complications 3 its popularity outgrew Ravitch procedure and currently is described as MIRPE - Minimally Invasive Pectus Excavatum Repair. 4 However afterward then many new techniques were developed, focusing on reducing overall procedure risks, improving patient safety and quality of life and including new technical possibilities. The aim of this study was to gather and evaluate current literature to highlight new treatment options. [ABSTRACT FROM AUTHOR]

Introduction The anterior cruciate ligament (ACL) is a prevalent sports-related injury, constituting nearly half of knee injuries. This narrative review explores the evolution of ACL reconstruction surgeries, emphasizing graft types and their pros and cons. Current state of knowledge The ideal ACL graft choice depends on factors like age, lifestyle, and demands. Autografts are the current standard, with the Quadriceps Tendon graft offering similar outcomes and fewer complications. Allografts are a secondary option for older, low-demand patients due to a shorter recovery period. Artificial grafts have limited use, lacking strong evidence for clinical advantages but may be considered for suturing torn ACL stumps and in cases were quick recovery is essential. Summary Contemporary orthopedic practitioners must possess comprehensive knowledge of various ACL reconstruction graft types to tailor interventions precisely to individual patient requirements. The selection of a graft should be rooted in a profound comprehension of patients' lifestyles, medical histories, and specific demands, thereby mitigating the subjective impact of any associated limitations for the patient. [ABSTRACT FROM AUTHOR]

Introduction: Alzheimer's disease (AD) remains a pervasive and challenging neurodegenerative disorder with profound implications for individuals, families, and societies. As the most prevalent cause of dementia globally, AD's prevalence is set to rise significantly in the context of an aging population. This introductory section emphasizes the urgent need for a comprehensive understanding of the disease, encompassing both its molecular intricacies and the socio-economic burden. With age being the primary risk factor, recent research has delved into the complex interplay of genetic predisposition and environmental influences, reshaping our understanding of AD from a multifactorial perspective. Current State of Knowledge: Advancements in Alzheimer's research have led to a nuanced understanding of its pathology. Traditionally characterized by amyloid-beta plaques and tau tangles, recent insights from neuroimaging and biomarker studies have revealed the intricate nature of these pathologies and their roles in disease progression. Genetic studies, including genome-wide association analyses, have identified susceptibility loci, notably the APOE gene. Simultaneously, environmental factors, such as air pollution and lifestyle choices, are recognized contributors to AD risk. The therapeutic landscape has evolved, with ongoing investigations into anti-amyloid and anti-tau therapies, lifestyle interventions, and precision medicine approaches. The synthesis of these diverse findings highlights the dynamic nature of Alzheimer's research and its potential to shape future treatment modalities. Summary: In summary, this article provides a comprehensive overview of the current state of knowledge regarding Alzheimer's disease. From understanding its evolving pathology to exploring the interplay of genetic and environmental factors, the multifactorial nature of AD is underscored. The therapeutic landscape is actively advancing, presenting a hopeful outlook for future treatments. [ABSTRACT FROM AUTHOR]

Introduction and purpose: Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had been spreading rapidly throughout the world, mainly affecting respiratory system. Except pulmonary symptoms, skin lesions might also occur. The precise percentage of patients with confirmed COVID-19 who presented cutaneous manifestations is still unknown (0.2% - 20.4%). Part of the skin lesions might be drug-induced. Brief description of the state of knowledge: Cutaneous manifestations in the course of the coronavirus disease could be divided into six main groups: maculopapular rash, urticarial lesions, chilblain-like lesions, vesicular eruptions, petechial/purpuric lesions and livedoid lesions. The most common skin lesions are maculopapular eruptions (47%). Trunk is the most affected location, whereas pruritus is the most frequent additional symptom among patients with skin lesions associated with coronavirus disease. These lesions appear mainly in elderly patients except pseudo chilblains which are present among children and young adults with SARS-Cov-2 infection. The majority of cutaneous manifestations occur after COVID-19 systemic symptoms, but the appearance of vesicular lesions before the respiratory signs was also reported. Cutaneous manifestations resolved spontaneously at different times, ranging from a few days to 2-4 weeks. Moreover, patients with severe course of COVID-19 with maculopapular rash have better prognosis (2% mortality rate) in comparison to patients who developed livedoid lesions in course of the coronavirus disease (10% mortality rate). Summary: Pseudo-chilblains and vesicular lesions are the most specific cutaneous manifestations of coronavirus disease. Healthcare professionals should pay attention to patients who present skin symptoms in the course of COVID-19. Cutaneous manifestations can facilitate the doctor the diagnosis and even estimate the severity of coronavirus disease. [ABSTRACT FROM AUTHOR]